JP7686581B2 - 認知機能の向上薬としてのメチルチオニニウム - Google Patents

認知機能の向上薬としてのメチルチオニニウム Download PDF

Info

Publication number
JP7686581B2
JP7686581B2 JP2021577642A JP2021577642A JP7686581B2 JP 7686581 B2 JP7686581 B2 JP 7686581B2 JP 2021577642 A JP2021577642 A JP 2021577642A JP 2021577642 A JP2021577642 A JP 2021577642A JP 7686581 B2 JP7686581 B2 JP 7686581B2
Authority
JP
Japan
Prior art keywords
nootropic
acid
compound
composition
nootropic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021577642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539185A (ja
JPWO2021001306A5 (https=
JP2022539185A5 (https=
Inventor
ロバート ハリントン，チャールズ
リーデル，ゲルノット
クライン，ヨヘン
シュワブ，カリマ
ミシェル ウィスチク，クロード
Original Assignee
ウィスタ ラボラトリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィスタ ラボラトリーズ リミテッド filed Critical ウィスタ ラボラトリーズ リミテッド
Publication of JP2022539185A publication Critical patent/JP2022539185A/ja
Publication of JPWO2021001306A5 publication Critical patent/JPWO2021001306A5/ja
Publication of JP2022539185A5 publication Critical patent/JP2022539185A5/ja
Application granted granted Critical
Publication of JP7686581B2 publication Critical patent/JP7686581B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
    • B65D25/34—Coverings or external coatings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2203/00—Decoration means, markings, information elements, contents indicators
    • B65D2203/02—Labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Mechanical Engineering (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Composite Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Physiology (AREA)
JP2021577642A 2019-07-01 2020-06-29 認知機能の向上薬としてのメチルチオニニウム Active JP7686581B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1909454.9 2019-07-01
GBGB1909454.9A GB201909454D0 (en) 2019-07-01 2019-07-01 Enhancers
PCT/EP2020/068229 WO2021001306A1 (en) 2019-07-01 2020-06-29 Methylthioninium as enhancers of the cognitive function

Publications (4)

Publication Number Publication Date
JP2022539185A JP2022539185A (ja) 2022-09-07
JPWO2021001306A5 JPWO2021001306A5 (https=) 2023-07-07
JP2022539185A5 JP2022539185A5 (https=) 2023-07-07
JP7686581B2 true JP7686581B2 (ja) 2025-06-02

Family

ID=67539959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577642A Active JP7686581B2 (ja) 2019-07-01 2020-06-29 認知機能の向上薬としてのメチルチオニニウム

Country Status (12)

Country Link
US (1) US20220330594A1 (https=)
EP (1) EP3989977A1 (https=)
JP (1) JP7686581B2 (https=)
KR (1) KR20220028045A (https=)
CN (1) CN114096254A (https=)
AU (1) AU2020298737B2 (https=)
BR (1) BR112021025330A2 (https=)
CA (1) CA3143417A1 (https=)
GB (1) GB201909454D0 (https=)
IL (1) IL289341A (https=)
MX (1) MX2021015289A (https=)
WO (1) WO2021001306A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3121169T3 (da) 2006-07-11 2022-02-28 Wista Lab Ltd Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser
DK3826639T3 (da) 2018-07-26 2024-09-23 Wista Lab Ltd Optimeret dosering af diaminophenothiaziner i populationer
KR102856378B1 (ko) 2022-09-30 2025-09-08 주식회사 젬백스앤카엘 4r 타우병증의 치료 또는 예방용 펩티드
AU2024231880A1 (en) 2023-03-03 2025-09-11 Taurx Therapeutics Management Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease
KR20240176447A (ko) 2023-06-15 2024-12-24 주식회사 젬백스앤카엘 신규 펩티드 및 이의 용도
KR102800994B1 (ko) 2023-11-06 2025-04-29 주식회사 엘지에너지솔루션 무음극 코팅층 및 이를 포함하는 전고체 전지

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530403A (ja) 2007-06-19 2010-09-09 ウイスタ・ラボラトリーズ・リミテッド 軽度認知障害を処置するためのフェノチアジン化合物
WO2018019823A1 (en) 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines
WO2018041739A1 (en) 2016-09-01 2018-03-08 Wista Laboratories Ltd. Treatment of dementia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
EP2013191B3 (en) 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
CA3027974C (en) 2007-10-03 2022-03-15 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
EA025033B1 (ru) 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
EP2705841A1 (en) 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530403A (ja) 2007-06-19 2010-09-09 ウイスタ・ラボラトリーズ・リミテッド 軽度認知障害を処置するためのフェノチアジン化合物
WO2018019823A1 (en) 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines
WO2018041739A1 (en) 2016-09-01 2018-03-08 Wista Laboratories Ltd. Treatment of dementia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BADDELEY T C; ET AL，JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS，2014年10月15日，VOL:352, NO:1，PAGE(S):110 - 118(1 - 9)，http://dx.doi.org/10.1124/jpet.114.219352
Biomed Research International，2016年，Vol.2016, Article ID3245935
Brain Imaging and Behavior，2017年，Vol.11，p.640-648
Journal of Alzheimer's Disease，2018年，Vol.61，p.435-457
Progress in Neurobiology，2012年，Vol.96，p.32-45

Also Published As

Publication number Publication date
GB201909454D0 (en) 2019-08-14
US20220330594A1 (en) 2022-10-20
JP2022539185A (ja) 2022-09-07
WO2021001306A1 (en) 2021-01-07
CA3143417A1 (en) 2021-01-07
KR20220028045A (ko) 2022-03-08
IL289341A (en) 2022-02-01
EP3989977A1 (en) 2022-05-04
CN114096254A (zh) 2022-02-25
MX2021015289A (es) 2022-01-18
AU2020298737B2 (en) 2026-03-05
BR112021025330A2 (pt) 2022-02-01
AU2020298737A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
JP7686581B2 (ja) 認知機能の向上薬としてのメチルチオニニウム
JP7080944B2 (ja) 細胞生存率を向上させるための組成物およびその使用方法
EP2167095B1 (en) Phenothiazine compounds for treating mild cognitive impairment
JP5730466B2 (ja) 鉄の細胞内不良処理からもたらされるフリードライヒ運動失調症の治療及び／又は予防のための方法およびデフェリプロンの使用
KR102559354B1 (ko) 치매 치료
US20190247379A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
EP4275750A2 (en) Treatment of alzheimer's disease in a particular patient population
US9161936B2 (en) Laquinimod for treatment of GABA mediated disorders
JP7638915B2 (ja) ロイコメチルチオニニウムの治療上の相互作用
CN113347961A (zh) 用于使用ly3154207治疗多巴胺能cns病症的剂量方案
RU2824584C2 (ru) Метилтиониний в качестве усилителя когнитивной функции
RU2834773C2 (ru) Терапевтические взаимодействия лейкометилтиониния
Samuels et al. Emerging therapeutics for Alzheimer's disease: an avenue of hope
Ligsay et al. Overview of targeted double-blind, placebo-controlled clinical trials in fragile X syndrome
Shua-Haim et al. Current and the near future medications for Alzheimer's disease: What can we expect from them?
WORKS Current
HK1136965A (en) Phenothiazine compounds for treating mild cognitive impairment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250501

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250521

R150 Certificate of patent or registration of utility model

Ref document number: 7686581

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150